What are the re-identification risk scores of publicly available anonymised clinical trial datasets?

What are the re-identification risk scores of publicly available anonymised clinical trial datasets?

We propose to randomly select several publicly available datasets from well known data repositories, and to calculate the re-identification risk scores using the methods described by El-Emam (2013). We will investigate what characteristics of the datasets are associated with increased or decreased risk scores, interpret all calculated risk scores and assess their usability, and discuss our findings. If issues arise with any particular dataset, they will be directly discussed with the datasets owners, and if appropriate, the issue will be reported as a result in this study, anonymised and unlinked to its original anonymised/de-identified dataset. There will not be any attempt to re-identify or contact individual patients.

[{ "PostingID": 537, "Title": "GSK-NAIA2008", "Description": "A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel and Group Study to Investigate the Efficacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections" },{ "PostingID": 3801, "Title": "GSK-DB2114930", "Description": "DB2114930: A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD" },{ "PostingID": 4514, "Title": "GSK-MEA115661", "Description": "MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects who participated in the MEA115588 or MEA115575 trials" },{ "PostingID": 4749, "Title": "NOVARTIS-CENA713DUS44", "Description": "A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44" },{ "PostingID": 5053, "Title": "EISAI-E2080-G000-303", "Description": "A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome" }]